NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third-quarter revenues increased 21 percent year over year, as the firm beat Wall Street estimates on the top and bottom line.

The San Diego-based genetic analysis tools firm reported total revenues of $285.9 million, up from $235.5 million for Q3 2011 and above analysts' consensus estimate of $284.8 million. Its product revenues climbed to $262.4 million from $220.3 million, and its service and other revenue jumped to $23.5 million from $15.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.